Literature DB >> 15737563

Management and outcome after local recurrence of osteosarcoma.

Robert J Grimer1, Scott Sommerville, David Warnock, Simon Carter, Roger Tillman, Adesegun Abudu, David Spooner.   

Abstract

We report on the management and outcome of 96 patients who developed local recurrence (LR) after having definitive primary treatment with chemotherapy and surgery for non-metastatic osteosarcoma. LR developed at a median of 11 months from initial surgical treatment. 18% of patients had metastases prior to the diagnosis of LR and 23% were found to have metastases synchronously. The prognosis for this group with metastases was 14% survival at 2 years. In the 57 patients without metastases at the time of development of LR, survival was 51% at 2 years and 41% at 5 years. Treatment was by excision of the LR and radiotherapy or by amputation. The only significant prognostic factors identified were the presence of metastases at the time of development of LR (P < 0.0001) and small size of the LR. The role of adjuvant chemotherapy was unclear. Whilst every attempt should be made to avoid LR, patients who develop LR are curable, particularly if they do not have metastases at the time of diagnosis of the LR.

Entities:  

Mesh:

Year:  2005        PMID: 15737563     DOI: 10.1016/j.ejca.2004.11.012

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  13 in total

1.  Local recurrence has only a small effect on survival in high-risk extremity osteosarcoma.

Authors:  Chang-Bae Kong; Won Seok Song; Wan Hyeong Cho; Jung Moon Oh; Dae-Geun Jeon
Journal:  Clin Orthop Relat Res       Date:  2011-10-19       Impact factor: 4.176

2.  Usefulness of increased 18F-FDG uptake for detecting local recurrence in patients with extremity osteosarcoma treated with surgical resection and endoprosthetic replacement.

Authors:  Kyoung Jin Chang; Chang-Bae Kong; Wan Hyeong Cho; Dae-Geun Jeon; Soo-Yong Lee; Ilhan Lim; Sang Moo Lim
Journal:  Skeletal Radiol       Date:  2014-11-29       Impact factor: 2.199

3.  What are the factors that affect survival and relapse after local recurrence of osteosarcoma?

Authors:  Akihiko Takeuchi; Valerae O Lewis; Robert L Satcher; Bryan S Moon; Patrick P Lin
Journal:  Clin Orthop Relat Res       Date:  2014-07-01       Impact factor: 4.176

4.  Management of local recurrence of pediatric osteosarcoma following limb-sparing surgery.

Authors:  Amos H P Loh; Fariba Navid; Chong Wang; Armita Bahrami; Jianrong Wu; Michael D Neel; Bhaskar N Rao
Journal:  Ann Surg Oncol       Date:  2014-02-21       Impact factor: 5.344

Review 5.  A review of clinical and molecular prognostic factors in osteosarcoma.

Authors:  Jonathan C M Clark; Crispin R Dass; Peter F M Choong
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-27       Impact factor: 4.553

6.  Role of surgical margin on local recurrence in high risk extremity osteosarcoma: a case-controlled study.

Authors:  Dae-Geun Jeon; Won Seok Song; Chang-Bae Kong; Wan Hyeong Cho; Sang Hyun Cho; Jeong Dong Lee; Soo-Yong Lee
Journal:  Clin Orthop Surg       Date:  2013-08-20

7.  Computer-assisted surgery in orthopedic oncology.

Authors:  Jasper G Gerbers; Martin Stevens; Joris Jw Ploegmakers; Sjoerd K Bulstra; Paul C Jutte
Journal:  Acta Orthop       Date:  2014-08-20       Impact factor: 3.717

8.  Magnetic resonance imaging features for the differential diagnosis of local recurrence of bone sarcoma after prosthesis replacement.

Authors:  Le Qin; Qiyuan Bao; Jie Chen; Lianjun Du; Fuhua Yan; Yong Lu; Caixia Fu; Weibin Zhang; Yuhui Shen
Journal:  J Orthop Translat       Date:  2018-10-29       Impact factor: 5.191

9.  Late post-operative recurrent osteosarcoma: Three case reports with a review of the literature.

Authors:  Xiuchun Yu; Sujia Wu; Xuquan Wang; Ming Xu; Songfeng Xu; Ye Yuan
Journal:  Oncol Lett       Date:  2013-04-29       Impact factor: 2.967

10.  The Surgical Treatment and Outcome of Nonmetastatic Extremity Osteosarcoma with Pathological Fractures.

Authors:  Zhi-Ping Deng; Yi Ding; Ajay Puri; Edward H M Wang; Ashish Gulia; Claire Durban; Xiao-Hui Niu
Journal:  Chin Med J (Engl)       Date:  2015-10-05       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.